Phagenesis
Phagenesis is a UK-based medical technology company that develops the Phagenyx neurostimulation system, using pharyngeal electrical stimulation to treat post-stroke neurogenic dysphagia. It sells capital equipment and single-use catheters directly to acute care hospitals in the US and Europe.
- Company typePrivate
- Founded2007
- HeadquartersManchester, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Phagenesis does
Phagenesis is a UK-headquartered medical technology company founded in 2007 by Dr. Conor Mulrooney and Professor Shaheen Hamdy from the University of Manchester to commercialize pharyngeal electrical stimulation (PES) for the treatment of neurogenic dysphagia, primarily in post-stroke patients. Its flagship product, the Phagenyx Neurostimulation System, consists of a touchscreen-controlled base station and a single-use dual-lumen treatment catheter (11.5F outer, 8F inner diameter) that delivers 10-minute daily treatments over 3-6 days. The therapy targets sensory nerves in the pharynx to drive neuroplasticity and restore the brain's coordination of swallowing, with clinical efficacy validated by 30+ peer-reviewed publications, 9 randomized controlled trials, and 13 mechanistic fMRI/MEG studies.
The company generates revenue through a direct enterprise sales model targeting acute care hospitals, comprehensive stroke centers, and academic medical centers in the US and Europe. Revenue streams include one-time capital equipment sales of the Phagenyx Base Station (under multi-year contracts) and recurring unit-priced sales of single-use treatment catheters (pay-as-you-go, 3-6 per patient course), supplemented by bundled implementation, training, and clinical support services. Pricing is quote-based and not publicly disclosed. Treatment is administered by speech-language pathologists in inpatient settings and requires no active patient participation, making the system usable for critically ill, ventilated, or tracheostomized patients.
Phagenesis holds FDA de novo clearance (October 2022) and EU MDR approval (August 2024), making Phagenyx the only commercially available PES treatment in both US and EU markets. The company is headquartered in Manchester, UK, with a US commercial headquarters in Nashville, Tennessee, and operates a headcount of 11-50 employees. Following a $42 million Series D financing in March 2024 led by EQT Life Sciences and Sectoral Asset Management, the company appointed Chad Hoskins as CEO in September 2024 to lead US commercialization. In January 2026, PES was included in the AHA/ASA stroke guidelines, and Stephen Oesterle (former Medtronic SVP) was appointed to the board in April 2026.
Phagenesis firmographics
Firmographics- Name
- Phagenesis
- Legal name
- Phagenesis Inc.
- Website
- https://phagenesis.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Phagenesis is a UK-based medical technology company that develops the Phagenyx neurostimulation system, using pharyngeal electrical stimulation to treat post-stroke neurogenic dysphagia. It sells capital equipment and single-use catheters directly to acute care hospitals in the US and Europe.
- Ownership category
- akta.pro rank
Phagenesis industry classification
Industry- Product category
- Neurostimulation Medical Devices
- NAICS
- Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)
- akta.pro primary industry
- Stroke & Vascular Neurology (HLAKAIAG)
- akta.pro secondary industry
- Swallowing (Dysphagia) & Feeding Therapy In-Home (HSABADAK)
Keywords
Where Phagenesis is headquartered
LocationHeadquarters
- HQ city
- Manchester
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Phagenesis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- Phagenyx System Sales (Base Station): Sale of the Phagenyx Base Station - an intuitive touchscreen device that delivers personalized pharyngeal electrical stimulation. Hospitals purchase the capital equipment system for use across their inpatient facilities.
- Treatment Catheter Sales: Recurring sales of single-use treatment catheters with embedded electrodes. Each patient treatment course requires 3-6 catheter uses over consecutive days, creating recurring revenue per patient treated.
- Professional Services & Training: On-site training, clinical implementation support, program initiation, and ongoing optimization services to help hospitals integrate Phagenyx into their standard of care.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Hospital System Purchase - Phagenyx Base Station |
| Unit Pricing | Pay-as-you-go | Treatment Catheters - Per Patient Course |
| Other | Multi-year contract | Implementation & Training Services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Phagenesis product offering
Product offeringCore offering
Phagenesis develops and commercializes the Phagenyx Neurostimulation System, a pharyngeal electrical stimulation (PES) device used in acute care hospitals to treat neurogenic dysphagia in adult post-stroke patients. The system combines a touchscreen Base Station with a single-use dual-action Treatment Catheter (stimulation plus feeding) that delivers 10-minute daily treatments over 3-6 days to restore brain-controlled swallowing function. The company generates revenue through direct hospital sales of the Base Station, recurring catheter sales per patient treatment course, and bundled implementation and training services.
Product overview
Phagenesis offers a single unified product, the Phagenyx® Neuromodulation System, which consists of two integrated components: a Treatment Catheter and a Base Station. The system delivers pharyngeal electrical stimulation (PES) therapy to restore swallowing control in patients with neurogenic dysphagia, primarily post-stroke. The Treatment Catheter (11.5F/8F dual-lumen design) provides both stimulation and feeding capability, while the Base Station features an intuitive touchscreen interface with electrode position monitoring. The system is designed for rapid, early bedside intervention with 10-minute daily treatments over 3-6 days.
Differentiator
Problem solved
Functional benefit
Brands
- Phagenyx: The Phagenyx System is a neuromodulation device using pharyngeal electrical stimulation (PES) to restore swallowing control in patients with neurogenic dysphagia post-stroke.
Products and services
- Phagenyx Neurostimulation System The Phagenyx Neurostimulation System is a pharyngeal electrical stimulation (PES) device that restores the brain's ability to initiate and coordinate safe swallowing in adult patients with neurogenic dysphagia post-stroke. The system consists of a touchscreen Base Station (EPSB3) and a single-use dual-action Treatment Catheter (PNX-1000) that combines electrical stimulation with feeding capability. It delivers 10-minute daily treatments over 3-6 days at the bedside in acute care hospital settings, requiring no active patient participation and indicated as an adjunct to standard dysphagia care.
- Implementation & Training Services Professional services delivered by Phagenesis clinical and sales teams to onboard acute care hospitals onto the Phagenyx system. Includes on-site comprehensive training for speech-language pathologists and clinical staff, program initiation support, clinical workflow integration, and ongoing optimization to help hospitals adopt PES as a standard of care for post-stroke dysphagia.
Quantifiable outcome
- 2x improvement in swallowing safety
- +6 more outcomes
Companies that use Phagenesis
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Phagenesis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Phagenesis partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and core.
- Atlantic Health SystemmajorStrategic hospital partner. Atlantic Health became among the first in New Jersey to use Phagenyx System at Morristown Medical Center and Overlook Medical Center. Partnership represents early commercial adoption in US market following FDA approval and AHA/ASA guideline inclusion.
- Stephen Oesterle, MDcoreAppointed to Board of Directors in April 2026. Dr. Oesterle is a MedTech industry veteran who previously served as Senior Vice President for Medicine and Technology at Medtronic for 14 years. Currently serves on boards of Baxter and Peijia Medical. Brings strategic guidance for US growth and global expansion.
- Banner - University Medical Center PhoenixmajorEarly US adopter and one of the first three facilities in the country using Phagenyx Neurostimulation System. Featured patient success stories including chef Michael John Coe. Clinical testimonials from SLPs and neurologists supporting the technology.
- AU Health (Augusta University Health)majorFirst acute care medical center in the United States to offer Phagenyx treatment. AU Health's Stroke Center was first in Georgia designated as Advanced Comprehensive Stroke Center. Early US adopter providing clinical evidence and case studies for the technology.
Scale indicators9 records
Recent moves6 records
Expansion highlights4 records
Phagenesis competitors and assessment
Company assessmentBroad incumbents
- Abbott: Abbott's neuromodulation business (formerly St. Jude) develops spinal cord and dorsal root ganglion stimulators and has established hospital neurology sales channels. It competes for the same hospital neurology capital budgets Phagenesis targets through Phagenyx.
- ElectroCore: ElectroCore develops vagus nerve stimulation (nVNS) therapies for neurological and inflammatory conditions. It shares the non-implantable neurostimulation modality and hospital-channel commercialization playbook that Phagenesis uses for PES.
- Inspire Medical Systems: Inspire is the leading hypoglossal nerve neurostimulator for obstructive sleep apnea and is the closest publicly traded analog for implantable/nerve-targeted neurostimulation hardware therapy sold direct-to-hospitals with disposable/recurring components.
- Medtronic: Medtronic operates the broadest portfolio of neurostimulation devices (DBS, spinal cord stim, sacral stim, ENT) including swallow-related therapies. It has the hospital neurology salesforce depth that Phagenesis is building against and represents both a competitor and potential acquirer.
Direct peers
- Penumbra: Penumbra is a leading interventional stroke device company (thrombectomy and stroke care) selling into the same comprehensive stroke center, neurology, and hospital purchasing channels that Phagenesis targets with Phagenyx.
- Passy-Muir: Passy-Muir is a leading maker of speaking valves and swallowing/secretion management devices for tracheostomy and dysphagia patients in inpatient and rehab settings. It directly overlaps with Phagenesis's clinical focus on restoring swallowing and airway function in post-stroke patients.
- Bionik Laboratories: Bionik Labs develops robotic rehabilitation technologies for post-stroke motor recovery deployed in inpatient and rehab hospitals. It sells into the same stroke rehab clinical buyer and is being studied as an adjunct for dysphagia-relevant neuroplasticity.
- Saebo: Saebo develops upper-limb rehab and orthotic devices used by occupational therapists in post-stroke patients in inpatient and outpatient settings. It targets the same SLP/OT clinical buyer addressing post-stroke deficits that Phagenesis targets with Phagenyx.
Others
- Avanos Medical: Avanos sells enteral feeding and PEG tube products (MIC-KEY, CORPAK) into the same stroke and dysphagia patient population treated by Phagenyx. It is an indirect competitor on the standard-of-care side that Phagenyx is trying to displace.
- Nestlé Health Science: Nestlé Health Science markets thickening agents, dysphagia nutrition products (Resource, ThickenUp), and is one of the standard-of-care options competing with Phagenyx. It addresses the same patient population via compensatory rather than restorative mechanisms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Phagenesis social profiles
Digital presencePhagenesis compliance and trust
Trust signalCompliance2 records
Phagenesis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phagenesis leadership team
Management profileNumber of profiles
Profiles19 records
Phagenesis funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phagenesis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phagenesis
What does Phagenesis do?
Phagenesis develops and commercializes the Phagenyx Neurostimulation System, a pharyngeal electrical stimulation (PES) device used in acute care hospitals to treat neurogenic dysphagia in adult post-stroke patients. The system combines a touchscreen Base Station with a single-use dual-action Treatment Catheter (stimulation plus feeding) that delivers 10-minute daily treatments over 3-6 days to restore brain-controlled swallowing function. The company generates revenue through direct hospital sales of the Base Station, recurring catheter sales per patient treatment course, and bundled implementation and training services.
Is Phagenesis a public or private company?
Phagenesis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Phagenesis founded?
Phagenesis was founded in 2007. It employs 11 to 50 people.
Where is Phagenesis based?
Phagenesis is headquartered in Manchester, United Kingdom, in the Europe region.
How does Phagenesis make money?
Three revenue lines are on record. Phagenyx System Sales (Base Station) is the primary driver. The others are treatment Catheter Sales and professional Services & Training.
Who are Phagenesis's main competitors?
Broad incumbents on record are Abbott, ElectroCore, Inspire Medical Systems and Medtronic. Direct peers are Penumbra, Passy-Muir, Bionik Laboratories and Saebo. Others are Avanos Medical and Nestlé Health Science.
Does Phagenesis have an API?
No public API is recorded for Phagenesis.
What industry is Phagenesis in?
Phagenesis's product category is Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAKAIAG, Stroke & Vascular Neurology, with a secondary code of HSABADAK, Swallowing (Dysphagia) & Feeding Therapy In-Home. Its NAICS code is 62134 and its SIC code is 3841.